Finance

One is a recent IPO, and the other can give investors international exposure.

A version rolling out next year will apparently contain a blood sugar monitor.

These shares aren’t for the faint of heart.

The company’s newly approved drug could generate billions in revenue per year.

These three Chinese companies are taking the electric scooter, e-commerce, and digital content market to new levels.

Just how risky is cryptocurrency? It depends on your strategy.

The tech company just isn’t a serious competitor, yet.

A value pick in the industrial sector.

These four companies are in the following high-growth markets: video streaming, e-commerce, cybersecurity, and audio streaming.

The science looks fishy for this small-cap biotech.

The controversy never ends with this biotech’s new Alzheimer’s drug.

These two companies are in a position to thrive as the world begins to recover from COVID-19.

With safety concerns allayed, the company is ready to restart clinical trials of key therapies.

This tech stock is growing at a terrific pace and looks primed for tremendous upside.

Tesla has undertaken many notable side projects in the past. But restaurants are much costlier than bottling a barrel of tequila.

After being a customer for two dozen years I finally bought into a stock I should have owned sooner.

The company experienced a boost in sales as folks stayed home during the pandemic.

If these four essential statements are true for you, you may have the answer you need.

These two multistate operators more than doubled investors’ money in 2020. Which is the better choice for investors right now?

With GXO’s Form 10 in the books, the separation is nearly complete.